Cancers, Journal Year: 2023, Volume and Issue: 15(16), P. 4014 - 4014
Published: Aug. 8, 2023
Cancer immunotherapies, while promising and occasionally even curative, encounter numerous hurdles within the tumor microenvironment that hinder their efficacy [...].
Language: Английский
American Journal of Roentgenology, Journal Year: 2024, Volume and Issue: 223(4)
Published: July 31, 2024
Treatment options are limited in patients with recurrent or metastatic disease after initial treatment of soft-tissue sarcoma (STS) by surgical resection, radiation, systemic therapy. Percutaneous cryoablation may provide a complementary minimally invasive option this setting.
Language: Английский
Citations
5
Photodiagnosis and Photodynamic Therapy, Journal Year: 2025, Volume and Issue: unknown, P. 104464 - 104464
Published: Jan. 1, 2025
Colorectal cancer (CRC) is one of the major cancers threatening human health, with high mortality, tumor drug resistance and metastasis, considered to be most difficult diseases treat. Due its advantages non-invasive, strongly targeted limit side effects, Photodynamic therapy (PDT) has become a promising primary treatment for CRC. Remarkably, PDT been shown activate T cell-adaptive immune response induce immunogenic cell death (ICD). Used in combination other techniques, considerable promise management colorectal cancer. In particular, immunotherapy, systemic anti-tumor was enhanced more significantly. This strategy expected achieve synergistic effect by inducing apoptosis, regulating microenvironment effectively activating immunity during process. review focuses on research combined immunotherapy improve studies, positive observed therapy, experimentally indicating new therapeutic opportunities
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: March 28, 2025
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, characterized by rapid proliferation, extensive infiltration, significant intratumoral heterogeneity. Despite advancements conventional treatments, including surgery, radiotherapy, chemotherapy, prognosis for GBM patients remains poor, with a median survival of approximately 15 months. Immunotherapy has emerged as promising alternative; however, unique biological immunological features, its immunosuppressive microenvironment (TME) low mutational burden, render it resistant to many immunotherapeutic strategies. This review explores key challenges immunotherapy, focusing on immune evasion mechanisms, blood-brain barrier (BBB), TME. Immune checkpoint inhibitors CAR-T cells have shown promise preclinical models but limited clinical success due antigen heterogeneity, cell exhaustion, impaired trafficking across BBB. Emerging strategies, dual-targeting cells, engineered secreting therapeutic molecules, advanced delivery systems overcome BBB, show potential enhancing treatment efficacy. Addressing these crucial improving immunotherapy outcomes.
Language: Английский
Citations
0
Journal of the American College of Surgeons, Journal Year: 2024, Volume and Issue: 238(6), P. 1122 - 1136
Published: Feb. 9, 2024
Language: Английский
Citations
2
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(14), P. 11434 - 11434
Published: July 14, 2023
Over the last several decades, a number of new treatment options for patients with hepatocellular carcinoma (HCC) have been developed. While decisions some remain clear cut, large numbers multiple options, and it can be hard multidisciplinary teams to come unanimous on which strategy or sequence treatments is best. This article reviews available data regard two strategies, immunotherapies locoregional therapies, focus potential therapies combined checkpoint inhibitors improve outcomes in locally advanced HCC. In this review, immunomodulatory effects discussed along clinical when strategies are combined.
Language: Английский
Citations
5
Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 205 - 234
Published: Aug. 28, 2024
Bispecific T-cell engagers (BiTEs) is a novel subclass of T-cell-engaging bispecific antibodies (bulbs) that are promising for the treatment cancer. BiTEs direct cytotoxic activity towards malignant cells, resulting in targeted destruction tumor cells. This chapter provides an overview current landscape BiTE therapy, highlighting its efficacy hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and exploring potential applications solid tumors. Additionally, challenges immunogenicity, stability, off-target effects were discussed, alongside ongoing efforts to overcome these obstacles through protein engineering combination therapies. Future directions therapy include optimizing delivery methods strategies. Overall, represents approach cancer treatment, with revolutionize immunotherapy improve patient outcomes.
Language: Английский
Citations
0
Clinical and Experimental Medicine, Journal Year: 2024, Volume and Issue: 25(1)
Published: Nov. 15, 2024
Metastatic disease and cancer recurrence are the primary causes of cancer-related deaths. Circulating tumor cells (CTCs) disseminated (DTCs) driving forces behind spread cells. The emergence development liquid biopsy using rare CTCs as a minimally invasive strategy for early-stage detection improved management is promising advancement in recent years. However, before blood sample analysis clinical translation, precise isolation from patients' based on their biophysical properties, followed by molecular identification single-cell multi-omics technologies necessary to understand heterogeneity provide effective diagnosis monitoring progression. Additionally, understanding origin, morphological variation, interaction between metastatic niche, well regulatory immune cells, will offer new insights into CTC-based advanced targeting future trials.
Language: Английский
Citations
0
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Dec. 13, 2024
Introduction The abscopal effect, a systemic anti-tumor response triggered by localized treatment, has gained attention but remains poorly understood. This study evaluates the efficacy and consistency of focused ultrasound (FUS) combined with immunotherapy in inducing effect. Methods A systematic review meta-analysis were conducted on preclinical studies using solid tumor models. Data response, immune modulation, survival outcomes analyzed to assess combination therapy's effectiveness. Results FUS enhanced responses at local distant sites, evidence activation increased effect rates. However, heterogeneity across models protocols was observed. Discussion findings provide theoretical basis for FUS-immunotherapy combinations cancer while emphasizing need standardized further research elucidate underlying mechanisms. Systematic registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42023460710.
Language: Английский
Citations
0
Cancers, Journal Year: 2023, Volume and Issue: 15(16), P. 4014 - 4014
Published: Aug. 8, 2023
Cancer immunotherapies, while promising and occasionally even curative, encounter numerous hurdles within the tumor microenvironment that hinder their efficacy [...].
Language: Английский
Citations
0